Castro-Oropeza R, Pia-Snchez P
The compound appears to upregulate eNOS (endothelial nitric oxide synthase), thereby increasing nitric oxide bioavailability in tissues
SUs are as effective as GLP-1RAs in HbA 1C reduction and have fewer GI effects, but they can lead to weight gain and also a higher risk of hypoglycaemia, which this patient needs to avoid
Individual Health Factors: Your health plays a role too
Tirzepatide treatment was administered at three final doses (5, 10, 15 mg per week), with treatment initiated at 2.5 mg and the dose escalated every 4 weeks
Design, synthesis and biological evaluation of glutathione peptidomimetics as components of anti-Parkinson prodrugs